epMotion for TruSeq, 6/14
June 2014—Eppendorf announced the epMotion automation method for Illumina’s TruSeq Stranded Total RNA library preparation kit for next-generation sequencing as “Illumina Qualified.”
Webinars and Sponsored Roundtables — Register Now
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace Directory
HTG Molecular Diagnostics and OvaGene Oncology partner, 6/14
June 2014—HTG Molecular Diagnostics and OvaGene Oncology entered a manufacturing supply agreement in which OvaGene will design and develop its proprietary gene expression assays on HTG’s fully automated, extraction-free Edge Platform.
Patient access to lab reports, 6/14
June 2014—Quest Diagnostics launched MyQuest by Care360 at QuestDiagnostics.com/MyQuest, a secure patient portal that enables patients to view copies of their lab test reports from Quest.
Digital particle analyzer, 6/14
June 2014—Arlington Scientific received FDA Center for Biologics Evaluation and Research clearance for the ASiManager-AT in rapid plasma reagin (RPR) interpretation and screening of blood donors.
Ready-to-use antibodies for cancer diagnosis, 6/14
June 2014—Dako added two new antibodies, Anti-CK 8/18 and Anti-TdT, to its portfolio. Anti-CK 8/18 is a rabbit monoclonal antibody cocktail for cytokeratin 8/18 to help classify tumors of unknown origin.
CellaVision expands product portfolio, 6/14
June 2014—CellaVision launched two new products, the CellaVision DM9600 (a replacement for CellaVision DM96), and CellaVision Advanced RBC Application, a software application for advanced analysis of red blood cells, both for use in clinical laboratories that handle large testing volumes and require a large capacity.
POC devices, 6/14
June 2014—The Minivette POC testing devices from Sarstedt are for the collection, transfer, and subsequent dispensing of small capillary blood samples for point-of-care tests. Blood is collected via capillary action into the collection capillary, the sample is held securely during transfer, and then it is dispensed onto the test field or into a micro tube with a slight push of the opposing integral piston.
High-performance centrifuge, 6/14
June 2014—Avanti JXN-26 centrifuges from Beckman Coulter have an intuitive interface and advanced data management features, including the ability to track and manage centrifuge runs remotely using MobileFuge, a mobile application for Apple iOS or Android devices.
Enterovirus monoclonal antibodies, 6/14
June 2014—ViroStat released a pan-reactive monoclonal antibody that is positive for all 27 enteroviruses tested to date.
Randox FDA-cleared controls, 6/14
June 2014—Randox’s Acusera HbA1c received FDA clearance. It is a 100 percent human whole blood, lyophilized control with assayed values provided for high-performance liquid chromatography and a wide range of clinical chemistry analyzers. When reconstituted the control remains stable for four weeks at 2°–8°C. The control is available in levels 1 and 2, and a calibrator is also available.